With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
It is the first branded generic alternative to Fostair 100/6 pMDI
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
The platform is being introduced to expand access to treatments for people living with chronic conditions
Subscribe To Our Newsletter & Stay Updated
